Retatrutide and trizepatide represent a recent class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists https://jonaspwhr356907.tokka-blog.com/39096202/new-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide